← All trials
NCT04584736
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2019
- Primary completion
- Jul 16, 2020
- Completion date
- Oct 12, 2020
- First posted
- Oct 14, 2020
- Last posted
- Oct 14, 2020
- Enrollment
- 283
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- JW PharmaceuticalLead sponsor
- JW PharmaceuticalStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.